Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/4165| Title: | Practical management of inflammatory bowel disease patients during the COVID-19 pandemic: expert commentary from the Gastroenterological Society of Australia Inflammatory Bowel Disease faculty | Authors: | Johnson, D. Costello, S. P. Ghaly, S. Connor, S. J. Begun, J. Christensen, B. Lewindon, P. Ward, M. G. Aysha, A. A. Rentsch, C. Prentice, R. Bryant, R. V. |
Issue Date: | 2020 | Source: | 50, (7), 2020, p. 798-804 | Pages: | 798-804 | Journal: | Internal Medicine Journal | Abstract: | The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has emerged as a public health emergency and challenged healthcare systems globally. In a minority of patients, SARS-CoV-2 manifests with a severe acute respiratory illness and currently there is insufficient data regarding the virulence of COVID-19 in inflammatory bowel disease patients taking immunosuppressive therapy. This review aims to summarise the current literature and provide guidance on the management of inflammatory bowel disease patients in the context of the COVID-19 pandemic in the Australasian setting.L20055440662020-07-20 | DOI: | 10.1111/imj.14889 | Resources: | https://www.embase.com/search/results?subaction=viewrecord&id=L2005544066&from=exporthttp://dx.doi.org/10.1111/imj.14889 | | Keywords: | public health;risk factor;smoking cessation;ulcerative colitis;vaccination;virus transmission;risk assessment;adalimumabazathioprine;budesonide;corticosteroid;golimumab;immunomodulating agent;infliximab;Janus kinase inhibitor;mercaptopurine;mesalazine;methotrexate;tofacitinib;ustekinumab;vedolizumab;article;coronavirus disease 2019;Crohn disease;diet therapy;health care quality;human;immunosuppressive treatment;inflammatory bowel disease;pandemic;patient care;priority journal | Type: | Article |
| Appears in Sites: | Children's Health Queensland Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.